SGIOF - ViiV's long-acting HIV therapy outperforms daily therapy in Phase 3 trial
2024-03-06 14:31:39 ET
More on GSK
- GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy
- GSK plc (GSK) Q4 2023 Earnings Call Transcript
- GSK plc 2023 Q4 - Results - Earnings Call Presentation
- Guggenheim upgrades GSK to buy from neutral
- Sen. Warren accuses GSK of price gouging over pediatric asthma drug